MGX.NASDAQMetagenomi, INC
DEF: Metagenomi, Inc. Announces 2025 Annual Meeting of Stockholders
Sentiment:
Proxy Statement
Metagenomi, Inc. will hold its 2025 annual meeting of stockholders virtually on June 10, 2025, to elect a director and ratify the appointment of its independent registered public accounting firm.
Summary
- Metagenomi, Inc. is holding its 2025 Annual Meeting of Stockholders on June 10, 2025, at 8:00 a.m. Pacific Time, as a virtual meeting.
- The meeting will include the election of Willard H. Dere, M.D. as a Class I Director to serve until the 2028 annual meeting.
- Stockholders will also vote to ratify the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
- The record date for determining stockholders eligible to vote is April 14, 2025.
- The company is providing proxy materials online, with instructions on how to access them and vote electronically, by phone, or by mail.
- As of the record date, 37,382,478 shares of common stock were outstanding and entitled to vote.
Sentiment
Score: 7
Explanation: The document is primarily informational and procedural, with a neutral to slightly positive tone due to the expression of gratitude and focus on future goals.
Positives
- The virtual meeting format enables stockholders to attend and participate from any location at no cost, providing cost savings and reducing environmental impact.
- The company has an independent lead director, independent committees, and regularly held executive sessions.
- The company has a Code of Business Conduct and Ethics, and policies on trading, pledging, and hedging of company stock.
- The company has a compensation recovery policy in place.
Negatives
- Sebastin Bernales, Ph.D., a member of the board of directors, has decided not to stand for reelection at the Annual Meeting.
Risks
- The document mentions enterprise risk management and major risk exposures, including financial, operational, privacy, security, cybersecurity, competition, legal, regulatory, hedging and accounting risk exposures.
- The company is subject to risks related to compensation, cybersecurity, and potential conflicts of interest.
Future Outlook
The company is focused on developing curative therapeutics using its genome editing toolbox.
Management Comments
- Brian C. Thomas, Chief Executive Officer, expressed gratitude for stockholders' continued support.
Industry Context
The company operates in the biotechnology industry, focusing on genome editing and therapeutics development.
Comparison to Industry Standards
- The document does not provide specific comparisons to industry standards.
- However, it mentions that the compensation committee considers compensation for comparable positions in the market, based on independent third-party benchmark analytics.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Sebastin Bernales, Ph.D. | N/A | June 10, 2025 | Dr. Bernales has decided not to stand for reelection. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Size | On January 13, 2025, the board approved an increase in the size of our board from five directors to six directors, and appointed Eric Bjerkholt, M.B.A. to serve as a director of our board effective January 27, 2025. | January 13, 2025 | Increase in board size to six directors. |
| Non-Employee Director Compensation Policy | In January 2025, our board of directors approved an amendment to our policy that provides that the Director Initial Award will be an award of 42,000 stock options; provided, however that the award shall be reduced so that the grant date fair value of the option is no greater than $600,000, and the Director Annual Grant will be an award of 21,000 stock options; provided that the award shall be reduced so that the grant date fair value of the option is no greater than $300,000. | January 2025 | Change in the number of stock options awarded to non-employee directors. |
Related Party Transactions
- Entities affiliated with Sozo Ventures purchased 133,333 shares of Common Stock in IPO for Aggregate Cash Purchase Price for Common Stock in IPO of $ 1,999,995.
Stakeholder Impact
- The election of directors and ratification of the accounting firm directly impact shareholders.
- Executive compensation policies affect employees and management.
- Corporate governance practices influence the company's overall operations and reputation.
Next Steps
- Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
- The company will hold its Annual Meeting on June 10, 2025.
- The company will continue to develop and execute its corporate strategy, including ESG initiatives.
Key Dates
| Date | Description |
|---|---|
| January 24, 2024 | Completion of the Reorganization where Metagenomi Technologies, LLC merged into Metagenomi, Inc. |
| February 2024 | Completion of the initial public offering (IPO). |
| December 31, 2024 | End of the fiscal year for which the annual report is provided. |
| March 11, 2025 | Sebastin Bernales, Ph.D. informed the Company that he has decided not to stand for reelection at the Annual Meeting. |
| April 14, 2025 | Record date for determining stockholders eligible to vote at the Annual Meeting. |
| April 28, 2025 | Commencement of sending the Notice of Internet Availability of Proxy Materials to stockholders. |
| June 9, 2025 | Deadline for voting via Internet or phone (11:59 p.m. Eastern Time). |
| June 10, 2025 | Date of the 2025 Annual Meeting of Stockholders at 8:00 a.m. Pacific Time. |
| December, 30 2025 | Deadline for stockholder proposals pursuant to Rule 14a-8 under the Exchange Act to be considered for inclusion in next years proxy statement. |
| February 11, 2026 | Earliest date for stockholders notice to be delivered to or mailed and received by us for stockholder nominations to our Board or other proposals to be considered at an annual meeting. |
| March 12, 2026 | Latest date for stockholders notice to be delivered to or mailed and received by us for stockholder nominations to our Board or other proposals to be considered at an annual meeting. |
Keywords
annual meeting, proxy statement, stockholders, directors, PricewaterhouseCoopers, corporate governance, executive compensation, audit committee, Metagenomi
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.